CPC technology class · G02
G02C - Spectacles
Spectacles; sunglasses or goggles insofar as they have the same features as spectacles; contact lenses. 6,144 US utility patents granted 2015–2025, with the leading assignees and year-by-year grant trajectory.
- 6,144
- US patents granted
- #3/3
- in G02
- 3.5%
- G02 class share
- +21%
- 5-yr velocity
The verdict
According to USPTO PatentsView, Spectacles ranks #231 of 670 CPC technology areas - 6,144 US patents granted since 2015, with recorded grant volume up 21% over five years.
- #231
- of 670 CPC technology areas
- 6,144
- US patents granted, 2015–2025
- Essilor International
- leading assignee (397)
- +21%
- grant velocity, last 5 yrs
How G02C's grant cadence moved
Between 2020–2024, G02C recorded 2,986 grants versus 2,462 in 2015–2019 (+21% equal-window velocity). Across complete years, output peaked in 2019 at 667 grants and bottomed in 2016 at 373 (+79% peak-over-trough). Lead assignee Essilor International holds 6.5% of the class ; the top three share 15.8%.
Leaderboard read
G02C concentration, lead at 6.5%
Essilor International leads this historical grant record at 6.5% of G02C - foreign corporation assignees hold 52% of class grants (2,268 of 4,325). Figures describe granted US utility patents in this CPC subclass, not current investment or legal strength.
- Leader's share
- 6.5%
- Top three share
- 15.8%
- Lead over #2
- 37
397 of 6,144 grants
of the class's recorded grants
more grants than Johnson & Johnson Vision Care, Inc.
Where G02C sits inside G02
Among 3 subclasses in G02 (Optics), G02C ranks #3 and holds 3.5% of the parent class's 174,596 recorded grants. Sibling chips below are the other subclasses in the same parent class, not the nationwide volume/lead-share peers further down.
Rising assignees active in G02C
Company-wide grant multiples (2022–2024 vs 2019–2021) among assignees with ≥5 patents in this subclass. Growth is company-wide; class patent counts are subclass-specific.
- #1 Meta Platforms Technologies, LLC 1285x 0 → 1,285 company-wide · 59 in G02C
- #2 Shenzhen Shokz Co., Ltd. 288x 0 → 288 company-wide · 68 in G02C
- #3 Innovega, Inc. 23x 1 → 23 company-wide · 25 in G02C
- #4 Twenty Twenty Therapeutics LLC 22x 1 → 22 company-wide · 6 in G02C
- #5 Hoya Optical Labs Of America, Inc. 16x 1 → 16 company-wide · 19 in G02C
G02C grants by year, peak 2019 (667)
US utility-patent grants per year in G02C, 2015–2025 - recent five years are up 21% versus 2015–2019.
Who leads G02C?
The 12 most active assignees in SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses - wider bars mean more grants
- Essilor International
Essilor International
397 patents
- Johnson & Johnson…
Johnson & Johnson Vision Care, Inc.
360 patents
- Snap
Snap Inc.
212 patents
- Carl Zeiss Vision… 149
Carl Zeiss Vision International GmbH
149 patents
- Verily Life Sciences 147
Verily Life Sciences LLC
147 patents
- Hoya Lens Thailand 114
Hoya Lens Thailand Ltd.
114 patents
- Magic Leap 109
Magic Leap, Inc.
109 patents
- Essilor International… 109
Essilor International (Compagnie Generale d'Optique)
109 patents
- Alcon 107
Alcon Inc.
107 patents
- Tectus 100
Tectus Corporation
100 patents
- Mitsui Chemicals 78
Mitsui Chemicals, Inc.
78 patents
- Brien Holden Vision… 72
Brien Holden Vision Institute Limited
72 patents
What this shows Essilor International is the most active filer in G02C, holding 397 of the 6,144 patents in this class. Concentration at the top signals how contestable this technology area is for new entrants.
View data table
| Rank | Company | Patents in G02C |
|---|---|---|
| #1 | Essilor International | 397 |
| #2 | Johnson & Johnson Vision Care, Inc. | 360 |
| #3 | Snap Inc. | 212 |
| #4 | Carl Zeiss Vision International GmbH | 149 |
| #5 | Verily Life Sciences LLC | 147 |
| #6 | Hoya Lens Thailand Ltd. | 114 |
| #7 | Magic Leap, Inc. | 109 |
| #8 | Essilor International (Compagnie Generale d'Optique) | 109 |
| #9 | Alcon Inc. | 107 |
| #10 | Tectus Corporation | 100 |
| #11 | Mitsui Chemicals, Inc. | 78 |
| #12 | Brien Holden Vision Institute Limited | 72 |
| #13 | Novartis AG | 70 |
| #14 | Coopervision International Limited | 70 |
| #15 | Shenzhen Shokz Co., Ltd. | 68 |
| #16 | AMO Groningen B.V. | 66 |
| #17 | Meta Platforms Technologies, LLC | 59 |
| #18 | Facebook Technologies, LLC | 58 |
| #19 | Oakley, Inc. | 58 |
| #20 | e-Vision Smart Optics, Inc. | 53 |
Footprint here vs. claim strategy
Each dot is a leading G02C assignee, placed by how many patents it holds in this class (horizontal) against its company-wide average claims per patent (vertical) - a read on whether the class is led by broad-but-shallow filers or focused deep-claim players.
Classes near G02C's 6,144-grant footprint
Nationwide nearest neighbors for G02C (#231 of 670 by volume ; lead share 6.5%) - not the G02 parent-class siblings above.
Nearest by grant volume
Questions about G02C
Which company holds the most patents in G02C?
Which G02C assignees grew fastest recently?
How does G02C compare inside parent class G02?
What to do with this data
G02C in context - here's where to go next.
- Essilor International leads G02C with 397 grants in this class. See full portfolio
- G02C ranks #231 of 670 by grant volume among all tracked CPC technology areas. See the ranking
- Inside parent class G02, the largest sibling subclass is G02B with 115,576 grants. Explore G02B
Figures reflect USPTO PatentsView grant data through 2026-05-15; pending applications not yet granted are not counted.
Methodology - G02C figures are USPTO PatentsView granted-utility totals for this subclass (6,144 grants in the tracked window).
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.